Atricure, Inc. · NASDAQ:ATRC
Atricure — Investor Presentation (January 2021)
26 slides from Atricure's investor presentation, Jan 11, 2021
Slide 1: AtriCure Investor Presentation: Creating a World Class Afib Platform
AtriCure Investor Presentation Creating a World Class Afib Platform January 202 1 © 2021 AtriCure, Inc. All rights reserved. AtriCure 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions
Slide 3: Focused on reducing the global Afib epidemic
We are passionately focused on reducing the global Afib epidemic and healing the lives of those affected Large Markets Addressing an underserved and growing patient population Strong Portfolio Existing products and solutions driving consistent growth Bright Future Novel therapies supported by growin
Slide 4: Afib: a Serious Problem
Afib: a Serious Problem Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 33 million people worldwide.1 Approximately 1.2 million Afib diagnoses annually in the US.2 5x Risk of Stoke >5x Higher risk of Heart Failure 46% Greater risk of all cause Mortality ©
Slide 5: US Market Opportunity
US Market Opportunity $350M Pain Management Procedures (Ablation) Boosting Growth via adjacent new market Estimated 140,000 thoracic patients annually $700-800M Concomitant Open Procedures (Ablation/LAAM) Steady Growth in penetration of Cardiac Surgery Market Estimated 300,000 total patients (Afib,
Slide 6: Significant Global Market Opportunity
Significant Global Market Opportunity US Market Focus Continued build of dedicated sales and training expertise Clinical data supporting multiple label expansions New product development Enhance reimbursement US market opportunity $3B+ annually International market opportunity $2B+ annually Internat
Slide 7: History of Strong Financial Performance
History of Strong Financial Performance Worldwide Revenue ($ Millions) $250 $150 $100 $50 $0 2015 $129.8 2016 $155.1 2017 $174.7 2018 $201.6 2019 $230.8 Revenue Growth 20.8% 19.5% 12.6% 15.4% 14.5% Gross Margin 71.6% 61.6% 72.2% 73.0% 73.8% Historical Results Consistent Revenue Growth Strong history
Slide 8: COVID-19 Response
COVID-19 Response Operationally, financially, and strategically positioning AtriCure for long-term growth Health & Safety Provide a safe work environment for our employees Enabling employees to work from home as appropriate Providing personal protection and other measures to ensure the safety of tho
Slide 9: 2021 Priorities: Building for the Future
2021 Priorities: Building for the Future Standalone Hybrid Procedures Ablation and LAAM Concomitant Open Ablation Pain Management COVID Recovery CONVERGE PMA approval and launch Re-engaging sites and training new accounts Addition of AtriClip to the Convergent procedure Continued global expansion of
Slide 10: CONVERGE Overview
CONVERGE Overview SUPERIORITY TRIAL designed to support FDA approval of the EPi-Sense devic e STUDY DESIGN Summary Multi-center, prospective, open label randomized 2:1 (Hybrid Convergent procedure vs endocardial catheter ablation) pivotal study Number of Subjects and Sites 153 subjects 27 sites (25
Slide 11: CONVERGE Trial Primary and Secondary Effectiveness
CONVERGE Trial Primary and Secondary Effectiveness17.7% differential 35.4% improvement23.2% differential 40.8% improvement19.6% differential 38.5% improvement Success (%) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Freedom from AF/AFL/AT 67.6% 50.0% p-0.036 >=90% Burden Reduction 80.0% 56.8% p= 0.00
Slide 12: Clinical Trial Patient Landscape
Persistent / Long-Standing Persistent AF Paroxysmal (30%)1 2.4 Million Patients Terminates spontaneously or with intervention within 7 days of onset Persistent (25%)' 2.0 Million Patients Sustained beyond 7 days but is less than 12 months in duration Clinical Trial Patient Landscape Long-Standing Pe
Slide 13: aMAZE Overview
aMAZE Overview SUPERIORITY TRIAL designed to evaluate safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage for the treatment of persistent or longstanding persistent AfibSTUDY DESIGN Summary Multi-center, prospective, open label randomized 2:1
Slide 14: Innovative and Expanding Product Portfolio
Innovative and Expanding Product Portfolio Ablation ISOLATOR® SYNERGY™ CLAMP cryoICE® CRYOABLATION PROBEEPI-SENSE® DEVICE cryoSPHERE® CRYOABLATION PROBE Future Product Launch: ISOLATOR SYNERGY ENCOMPASS® CLAMP2000 to 2015: Foundation in surgical Afib tools Future pipeline expansion across franchises
Slide 15: SPOTLIGHT: Cryo Nerve Block for Pain Management
SPOTLIGHT: Cryo Nerve Block for Pain Management Therapy Overview Long-lasting pain management therapy, designed for use in thoracic surgical procedures Temporarily stops transmission of pain signals coming from the chest wall during surgery Nerve “scaffolds” remain intact allowing axons to regenerat
Slide 16: Aligning Expertise with Opportunity
Aligning Expertise with Opportunity Commercial Teams 54 U.S. Sales Managers Covering 1,000+ accounts 64 U.S. Clinical Specialists providing case support 30 U.S. Dedicated MIS+Lariat team members 14 U.S. Specialists Cryo Nerve Block Team 33 U.S. Education Support Physician + Field 39 International Sa
Slide 17: Thank You!
Thank You! © 2021 AtriCure, Inc. All rights reserved. AtriCure 17
Slide 18: Supplemental Information
Supplemental Information Note that citations/references for any comments, statistics, or figures in this presentation are available upon request. © 2021 AtriCure, Inc. All rights reserved. AtriCure 18
Slide 19: Key Investment Rationale
Key Investment Rationale Large Markets Addressing an underserved and growing patient population Approximately 33 million Atrial Fibrillation patients globally, with majority having advanced forms of the disease1 Multibillion dollar annual market opportunity Current standard of care for intervention
Slide 20: Two Distinct Patient Profiles
Two Distinct Patient Profiles Referring Physician: GP, Cardiologist STRUCTURAL HEART ISSUE Surgery required – Afib corrected at same time (Valve, CABG) GUIDELINES15 Surgical Ablation is RECOMMENDED LAA management is REASONABLE Concomitant Open Procedures (Ablation/LAAM) NO STRUCTURAL ISSUE Afib is p
Slide 21: US Concomitant Market Opportunity
US Concomitant Market Opportunity Estimated Afib Opportunity in Cardiac Surgery Annual Cardiac Surgeries19 300,000 Pre-Operative Afib Rate17 ~28% Cardiac Opportunity – Pre-Op Afib 85,000 ASP Mix (Ablation and Appendage Management)20 $4,500 Open Cardiac Surgery Opportunity – Afib $382M Estimated Non-
Slide 22: US Standalone Market Opportunity
US Standalone Market Opportunity Estimated Standalone Afib Opportunity 2020 Projected 2025 Long-standing Persistent Afib Catheter Ablation23 25,000 45,000 ASP Mix (Ablation + Appendage Management)20 $15,000 $15,000 Immediate Standalone Afib Opportunity $375M $675M Additional penetration Long-standin
Slide 23: The CONVERGENT Approach
The CONVERGENT Approach Aorta PA SVC Pericardial Reflections RA Epicardial Lesions of Convergent Procedure Endocardial Lesions of Convergent Procedure © 2021 AtriCure, Inc. All rights reserved. AtriCure 23
Slide 24: The LARIAT Procedure
The LARIAT Procedure 1 Access: Routine percutaneous techniques for pericardial and transseptal access are performed using fluoroscopy and transesophageal echocardiography. 2 Delivery: Two magnet-tipped guidewires (FindrWIRZ®) are attached to stabilize the LAA with minimal trauma and manipulation for
Slide 25: The Cox-Maze IV Procedure
The Cox-Maze IV Procedure Left Atrial Appendage Coronary Sinus Mitral Annulus Circumflex Coronary Artery SVC Right Atrial Appendage Right Coronary Artery Tricuspid Annulus IVC Bipolar RF Clamp Surgical Incisoin Cryo – Endocardial Cryo- Epicardial © 2021 AtriCure, Inc. All rights reserved. AtriCure 2
Slide 26: Endnotes and Abbreviations
Endnotes and Abbreviations Note Reference 1 Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study 2 The American Journal of Cardiology (2013), 112: 1142-1147 3 J Geriatr Cardiol. 2016 Oct; 13(10): 880–882, doi: 10.11909/j.issn.1671-5411.2016.10.004 4 Santhanakrishnan R